Author(s):
Targeted Protein Degradation (TPD) represents a transformative therapeutic strategy, leveraging the body’s ubiquitin-proteasome system to eliminate disease-causing proteins. This approach, exemplified by PROteolysis TArgeting Chimeras (PROTACs) and molecular glues, has shown significant promise, especially in oncology, by targeting previously undruggable proteins and overcoming drug resistance. While facing challenges in clinical translation, the field is rapidly advancing, exploring diverse E3 ligase hijackers and expanding into new therapeutic areas beyond cancer, paving the way for next-generation medicines and improved patient outcomes
